In China, the majority of patients with hepatocellular carcinoma (HCC) result from long-term infection of hepatitis B. Pathologically, HCC is characterized by rich blood supply, multicentric origins, early vascular invasion and intrahepatic metastasis. Therefore, HCC is not a local disease but a systemic disease at the beginning of its occurrence. For this reason, a comprehensive treatment strategy should be adopted in the management of HCC, including local treatments (such as surgical resection, radiofrequency ablation, microwave ablation, chemical ablation and cryoablation, etc.), organ-level treatments [such as transcatheter arterial infusion of chemotherapy and transcatheter arterial chemoembolization (TACE)], and systemic treatments (such as immunotherapy, antiviral therapy and molecular targeted therapy, etc.). This consensus sets forth the minimally-invasive and multidisciplinary comprehensive guideline of HCC, focusing on the following...
eight aspects (1) using hepaticarteriography, CT hepatic arteriography (CTHA), CT arterial portography (CTAP), lipiodol CT (Lp-CT), TACE-CT to find the intrahepatic lesion and make precise staging (2) TACE combined with ablation or ablation as the first choice of treatment for early stage or small HCC, while other therapies are considered only when ablation is not applicable (3) infiltrating HCC should be regarded as an independent subtype of HCC (4) minimally-invasive comprehensive treatment could be adopted in treating metastatic lymph nodes (5) multi-level subdivision of M-staging should be used for individualized treatment and predicting prognosis (6) HCC with severe hepatic decompensation is the only candidate criterion for liver transplantation (7) bio-immunotherapy, traditional Chinese medicine therapy, antiviral therapy, and psychosocial and psychopharmacological interventions should be advocated through the whole course of HCC treatment (8) implementation of multicenter randomized controlled trials of minimally-invasive therapy versus surgery for early and intermediate stage HCC is recommended.

Keywords: hepatocellular carcinoma, minimally-invasive therapy, multidisciplinary comprehensive treatment, consensus, Guangzhou recommendations

INTRODUCTION

Primary liver cancer is the fourth most common malignant tumor and the third leading cause of cancer death in China, which seriously threatens the lives and health of Chinese people. Hepatocellular carcinoma (HCC) accounts for 85% to 90% of primary liver cancer (1, 2). In China, chronic hepatitis B virus (HBV) infection is the main cause of HCC. Approximately 85% of HCC cases are associated with HBV infection, and only approximately 10% are associated with hepatitis C virus (HCV) infection. Conversely, approximately 70% of HCC cases in European countries, North America, and Japan are associated with alcohol and HCV infection (1, 3). China has a large population of patients with liver cancer. There is not yet a worldwide consensus on the treatment strategy for liver cancer, and there is significant divergence in the guidelines for liver cancer treatment in different countries. The epidemiological characteristics, pathogenesis, biological behaviors, staging, diagnosis, treatment, and prognosis of HCC in China are significantly different from those in Europe, North America, and Japan. Therefore, the HCC guidelines developed by the Liver Disease Associations of the European countries, North America, and Japan are not fully applicable to HCC diagnosis and treatment in China. Even the “guidelines or expert consensus” representing the opinions of professionals in different disciplines or different societies are controversial in China. In China, the vast majority of HCC cases result from long-term HBV infection and cirrhosis development. Pathologically, HCC is characterized by a rich blood supply and multicenter origins, with early invasion of small branches of the portal vein and intrahepatic metastasis. Therefore, HCC is not only a local organ disease but also a systemic disease from the beginning of its occurrence (4).

In recent years, with the continuous advancement of minimally invasive interventional treatment techniques for HCC guided by imaging and studies of related large-scale randomized clinical trials, the efficacy of minimally invasive interventional therapy has been enhanced. In the meantime, the benefits of a multidisciplinary comprehensive treatment regimen for HCC have also been widely recognized in the clinic. In 2015, Minimally Invasive Therapy in Oncology of Chinese Anti-Cancer association published an article in the "National Medical Journal of China" (also called “Zhonghua Yi Xue Za Zhi”) to preliminarily describe the strategy for minimally invasive, multidisciplinary and comprehensive diagnosis and treatment of HCC (5). On the basis of the preliminary strategy, this consensus further summarizes previous achievements and experience in HCC treatment and highlights the following trends in HCC treatment: 1. More accurate diagnosis and staging; 2. Interventional and minimally invasive treatment, biological immunotherapy, Chinese herbal medicine, psychosocial and psychopharmacological interventions, and humanistic care, which constitute the basic framework for a modern HCC treatment approach; 3. Further explanation of the “constructive treatment concept and strategy” for tumors consistently advocated by the authors, i.e., while effectively inactivating the tumor, the physiological functions, immune function, and quality of life of the patients are optimally preserved. When choosing treatment strategies and methods, minimally invasive interventional therapy combined with multidisciplinary comprehensive treatment is preferred, and extensive wound damage should be avoided or reduced as much as possible. This consensus integrates the clinical diagnosis and treatment strategies of HCC in China and aims to reflect the individualized, rational, and humanistic features of a constructive treatment regimen for HCC.

DIAGNOSIS

HCC diagnosis comprises two major aspects: clinical diagnosis and pathological diagnosis. Clinical diagnosis primarily depends on determination of cirrhosis history caused by chronic hepatitis
(HBV and/or HCV) infection and/or other causes, serological diagnosis, and imaging diagnosis.

Serological Diagnosis
More than 60% of HCC patients in China show serum alpha-fetoprotein (AFP) levels $>$400 ng/mL. Therefore, AFP is of significant importance for surveillance and diagnosis of HCC in China (6). For patients with AFP $>$400 $\mu$g/L for more than 1 month, $\geq$200 $\mu$g/L for 2 months, or a gradually increased and stabilized AFP level but without pregnancy, gonadal embryo, or active liver disease, HCC should be highly suspected. However, notably, when the AFP level is normal or below the diagnostic criteria, HCC cannot be completely excluded. Approximately 30% of patients with HCC have AFP levels below 20 ng/mL, and 10% to 42% of AFP abnormalities are caused by pregnancy, gonadal embryo, active hepatitis, the active inflammatory stage of cirrhosis, or metastatic liver tumors (7). Therefore, AFP cannot be used as the only indicator for HCC surveillance and diagnosis. At present, many studies have found that des-$\gamma$-carboxy prothrombin (DCP) [also known as protein induced by vitamin K absence or antagonist (PIVKA) II] and AFP-L3/AFP assessments can improve the sensitivity and specificity of early liver cancer diagnosis. DCP $>$40 mAU/mL or AFP-L3/AFP $>$15% suggests the possibility of liver cancer (8). Application of the methylation spectrum of circulating tumor DNA (ctDNA) in the diagnosis of tumors, which is one of the “liquid biopsy” markers, is a hotspot in the field of cancer research using circulating tumor nucleic acids. Xu et al. (9) examined the methylation level of specific loci on ctDNA using a few milliliters of blood for early diagnosis of HCC and achieved a diagnostic sensitivity of 84.8% and a specificity of 93.1%.

Imaging Diagnosis
Imaging plays a crucial role in HCC diagnosis. Currently, the imaging examination methods used for HCC diagnosis primarily include ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), digital subtraction angiography (DSA), and positron emission tomography (PET)/CT. Dynamic enhanced CT and/or MRI are the main diagnostic tools for HCC. CT arterial portography (CTAP)/CT hepatic arteriography (CTHA) combined with lipiodol CT (Lp-CT) can improve the sensitivity and specificity of HCC diagnosis (especially for lesions with a diameter $<$1 cm). However, since CTAP, CTHA, and Lp-CT are invasive diagnostic procedures, they are used as secondary imaging-based diagnostic methods for HCC. Ultrasound examination is easily available and convenient to perform for initial HCC screening, but the results tend to be affected by the skill of the operators, equipment, liver texture, patient’s body build, obstacles from bone and air. In addition, cholangiocarcinoma tends to contribute to false positive findings in contrast-enhanced ultrasound. PET/CT is beneficial in small population for evaluating the extension of HCC. Therefore, ultrasonography and PET/CT are not included in the present HCC diagnostic criteria. Moreover, diagnosis of specific liver cancer types should be emphasized, such as infiltrative and small HCC.

As the primary imaging-based diagnostic method, the characteristic manifestations indicative of HCC diagnosis observed with dynamic contrast-enhanced CT and/or MRI are arterial phase enhancement and washout during the portal venous phase or delayed phase (10, 11). Statistically, the specificity of dynamic enhanced CT and/or MRI for diagnosis of lesions 1-2 cm in diameter with typical nodule manifestations is 96.6%, and the sensitivity is 62%. For nodules with a diameter $>$ 2 cm, the sensitivity reaches 96% (12, 13). Therefore, for nodules with a diameter $>$1 cm, when dynamic enhanced CT and/or MRI demonstrate arterial phase enhancement and washout during the portal venous phase or delayed phase, HCC should be highly suspected. However, attention should be paid to the specific manifestations of infiltrative HCC. Infiltrative HCC is defined as an HCC lesion with unclear borders diffusely distributed in multiple hepatic segments, occupying an entire hepatic lobe or the entire liver. Infiltrative HCC accounts for 7% to 13% of all HCC cases. It is more commonly seen in patients with HBV infection, frequently associated with portal vein tumor thrombosis, and has a poor prognosis. Infiltrative HCC is often accompanied by cirrhosis and produces nodules similar to cirrhosis, which is difficult to detect with CT and MRI. MRI diagnosis is more meaningful than CT and is based on an uneven, slightly lower signal on T1 WI, a slightly higher signal on T2 WI, limited diffusion, mostly uneven or miliary enhancement in the arterial phase, and no washout in the portal venous phase, which, in contrast, demonstrates continuous enhancement (14, 15). Due to the poor sensitivity of dynamic enhanced CT/MRI in the diagnosis of HCC lesions smaller than 1 cm, the current European and American diagnostic criteria only apply to HCC larger than 1 cm, and the diagnostic value of liver-specific contrast agents is not emphasized in those guidelines. Although liver-specific contrast agents can improve the diagnostic rate of MRI for HCC smaller than 1 cm, the sensitivity is still low (approximately 46%) (16). When HCC is highly suspected in clinical practice, and CT and MRI cannot detect a lesion with a typical imaging manifestations, work-up with combined application of secondary imaging diagnostic methods should be done.

As a secondary imaging diagnostic method, CTAP reveals a HCC on the basis of portal venous blood supply, which is displayed as a filling defect on the background of highly enhanced normal liver tissue. On CTHA, HCC appear as enhanced nodules at arterial phase, which should be distinguished from arterial-portal shunt and abnormal perfusion. CTHA combined with CTAP can reduce the false positive rate and significantly improve diagnostic sensitivity (from up to 80% to 95%) and specificity for HCC (especially lesions with a diameter $\leq$1 cm) (17). Some studies have found that CTHA/CTAP can detect 32.8% of lesions that are not detected with dynamic enhanced CT, especially in patients with an HBV (-) status, multiple nodules, and intrahepatic recurrence or metastasis after treatment (18, 19). CTHA/CTAP can accurately assess the extent of the lesion and identify disseminated intrahepatic foci. In the meantime, CTHA/CTAP is more sensitive to intrahepatic hemodynamic changes, which is beneficial for assessment of the infiltration status of intrahepatic blood vessels (even tiny blood vessels) (20, 21). Therefore, CTHA/CTAP provides more precise
pretreatment tumor staging and facilitates selection of the optimal treatment choice. Clinically, approximately 15% of small HCC lesions or foci cannot be detected by CTHA/CTAP and require combined examination via Lp-CT (22–26). The Lp-CT is performed by injecting 3 to 4 mL of lipiodol through the hepatic artery, followed by liver CT 2 weeks later, and HCC is manifested as intrahepatic lipiodol deposition foci. Lipiodol deposits in HCC are generally dense and uniform, and lipiodol deposits in some necrotic HCC are incomplete and distributed in the periphery or center of the lesion. Lp-CT is of significant importance for detection of HCC with a low degree of differentiation, micro-HCC, small lesions with multicenter origins and intrahepatic micrometastases, and lipiodol also has certain therapeutic effects (22, 27, 28). As early as in 2003, Wu and co-editors monographed a book in Chinese “Minimally Invasive and Multidisciplinary Comprehensive Treatment of Hepatocellular Carcinoma” detailed the diagnosis and treatment of micro-HCC (29). Micro-HCC is defined as follows: 1. Lesion diameter ≤ 0.5 cm; 2. Clinically elevated AFP level (AFP ≥ 400 µg/L for more than 1 month or ≥ 200 µg/L for 2 months); 3. Lesions that were detected by CTAP/CTHA or and present as spotted lipiodol deposits in Lp-CT; 4. AFP decreased or returned to normal level after Lp-CT or transcatheter arterial embolization (TAE). In view of the invasiveness and high cost of CTHA/CTAP and Lp-CT, these examinations are recommended as secondary diagnostic tools or combined with transarterial chemoembolization (TACE) or TAE to facilitate accurate diagnosis and staging and to simultaneously achieve therapeutic goals.

Pathological Diagnosis
Pathological diagnosis of HCC is recommended when imaging examination shows noncirrhotic liver nodules, uncertain or atypical imaging findings in a cirrhotic liver, or when serology and imaging diagnoses are contradictory. Studies have found that the positive biopsy rate of lesions smaller than 2 cm is only approximately 60% (30), and therefore, negative biopsy results do not completely rule out HCC diagnosis, and still requires further diagnostic work-up or clinical follow-up. Figure 1 shows the HCC diagnosis process.

TREATMENTS
HCC occurrence and development are complicated dynamic processes involving multiple factors that are conjoined in multiple steps and include different modifications and gene mutations in many molecular pathways. HCC usually originates from chronic hepatitis, proceeding to cirrhosis and then to HCC. In China, the majority of liver tumors have a rich blood supply, and are accompanied by a background of hepatitis or cirrhosis, and exhibit multicenter occurrence, portal vein tumor thrombus and intrahepatic dissemination even at the its early presentation (4). Therefore, single local treatment cannot achieve a curative effect, and a comprehensive treatment regimen should be adopted that includes local treatment (surgery and ablation) combined with organ level treatment (TACE and perfusion chemotherapy) and systemic treatment (psychotherapy, antiviral treatment, molecular targeting, biological immune therapy, and Chinese traditional medicine treatment).

This consensus emphasizes that minimally invasive treatment should be considered first for early-stage HCC when tumor ablation is safe. If minimally invasive treatment is not applicable for the patient after detailed evaluation, the more traumatic surgical treatment can be considered. The various current treatments and comprehensive treatment principles are described below.

Local Ablation
Local ablation is minimally invasive, safe, effective, and can be performed repeatedly. Ablation methods include physical ablation (such as radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, high intensity focused ultrasound (HIFU) ablation, and irreversible electroporation (IRE) ablation) and chemical ablation [such as percutaneous ethanol injection (PEI) or percutaneous acetic acid injection (PAI)]. For single HCC lesion with a diameter ≤ 2 cm, local ablation treatment can achieve long-term efficacy similar to or superior to surgical treatment, with the advantages of less liver function damage, fewer complications, faster recovery, and shorter hospitalization and therefore should be considered the top option (31–33). For a single HCC lesion with a diameter of 3 to 5 cm or 2 to 3 lesions with diameters < 3 cm, the therapeutic effect can be improved by combining TACE treatment with a suitable ablation technique (34). For tumors with a diameter of more than 5 cm or more than three tumor lesions, local ablation cannot inactivate all of the tumor tissue; small satellite lesions are easily missed, and the local recurrence rate is high. Therefore, TACE combined with ablation is significantly superior to ablation alone under these circumstances. A potential drawback is that such combination requires two consecutive treatment sessions, which poses an increased risk for multifocal tumor recurrence or focal progression through repeated manipulation (35). For a tumor to be considered inside the ablation safety zone, the lesion must not be close to or contiguous to the gallbladder, the hilum of the liver, stomach, intestines, or the heart. Ablation of tumors in these dangerous areas may require comprehensive ablation methods, including the water insulation technique (hydrodissection), combined with chemical ablation and particle (125I seed) implantation.

RFA and MWA are the most widely used local ablation techniques, with well documented therapeutic effects. When the lesion is larger than 2 cm, RFA is superior to PEI. For tumors adjacent to a large blood vessel or for a large tumor, the effect of MWA may be better due to its shorter ablation procedure time, larger ablation zone, and lower heat sink effect compared with RFA. However, the current RFA and WMA comparison studies show no significant difference in local efficacy and occurrence of complications between the two methods (36–38). Cryospheres formed by cryoablation can be easily observed at imaging (especially CT and MRI) studies, which is convenient for controlling the ablation zone to avoid damaging surrounding normal structures or tissues. However, the incidence of complications, such as hemorrhage, in cryoablation is significantly higher than that in RFA, and thus, cryoablation is not widely used in liver cancer treatment (39, 40). HIFU, by combining non-touch, conformal, and real-time treatment, has advantages for the treatment of multiple tumors and/or liver cancer in some specific locations. However, HIFU treatment takes a longer time, and it is
FIGURE 1 | Flowchart of HCC diagnosis. The flowchart is mainly applicable to the diagnosis of HCC patients with HBV and/or HCV infection or a liver cirrhosis background related to various causes. For intrahepatic space-occupying lesion patients without hepatitis or a cirrhosis history, diagnosis is usually made by using biopsy; or serological diagnosis including AFP, AFP-L3, or DCP detection. Serological diagnosis (+) refers to AFP > 400 µg/L for more than 1 month or ≥ 200 µg/L for 2 months, DCP > 40 mAU/mL or AFP-L3/ AFP-L3<400 µg/L for 2 months. Hyperdynamic enhancement during the arterial phase and washout during the portal venous phase or delayed phase; Nodule enhancement in CTHA, filling defect in CTAP and lipiodol deposits in the nodules 2 to 3 weeks after lipiodol injection revealed by Lp-CT; Nodule (-) does not rule out the possibility of HCC, which still requires close follow-up; Micro-HCC is defined as follows: 1. Lesion diameter ≤ 0.5 cm; 2. Clinically elevated AFP (AFP ≥ 400 µg/L for more than 1 month or ≥ 200 µg/L for 2 months); 3. Lesions that were detected by CTAP/CTHA or/and present as spotted lipiodol deposits in Lp-CT or TACE; Refers to noninvasive infiltration and diffuse distribution of lesions with an unclear boundary in the liver. T1 WI shows an uneven, slightly low signal, and T2 WI shows a slightly high signal, limited diffusion, and uneven or milia enhancement or slight enhancement in the arterial phase and no washout in the portal venous phase, which instead would demonstrate continuous enhancement; For nodules with a diameter of more than 1 cm with typical imaging manifestations, when serological diagnosis is negative, the lesions should be distinguished from primary HCC and other rare pathological types. If the patients choose nonsurgical treatment, a needle biopsy is recommended.
relatively difficult to locate the tumor. Color Doppler ultrasound monitoring can be performed in real-time and is convenient; however, due to the interference of the ribs and gastrointestinal gases, the efficacy of this treatment is dependent on the operator’s experience and skill. Furthermore, the high echo shadow generated during ablation affects observation of the treatment efficacy. HIFU treatment has the deficiencies of therapeutic dosimetry and unclear effects on normal tissues (nonablation areas) after therapeutic ultrasound. Clinically, there is a lack of studies comparing HIFU with other ablation treatments, and thus, the efficacy of HIFU is difficult to evaluate (41–43). As a new nonthermal ablation technique, IRE employs high voltage to irreversibly damage cell membranes and induce apoptosis. IRE treatment has the advantages of a short procedure time, precise ablation zone, no influence of a heat sink effect, and no damage to large blood vessels or bile ducts. Therefore, IRE provides a new option for HCC treatment at certain locations (such as lesions adjacent to large blood vessels and bile ducts and the subcapsular area). However, its effectiveness and safety still await validation in larger cohorts of patients (44–46).

**Surgical Treatment**

Surgical treatment is one of the main treatments for HCC and includes liver resection and liver transplantation. For patients in good general condition with a sufficient liver function and remnant liver (15-min retention rate of indocyanine green test <14%), and no severe disease involving the heart, lung, kidney, or other important organs, hepatectomy can be performed. The indications for liver transplantation in patients with HCC are controversial. In China, the incidence of HCC is high, donor livers are not easily available, the cost of transplantation is high, and long-term use of immunosuppressive drugs after liver transplantation is necessary, which leads to inevitable postoperative recurrence. This situation is incompatible with the rapid development and progress in tumor immunology research in the past 10 years. Therefore, liver transplantation is not the first choice or routine treatment for HCC, especially for the treatment of early-stage HCC without cirrhosis decompensation and liver failure.

**Hepatic Artery Interventional Treatments**

Trans-arterial interventional treatments for HCC primarily include TAE, TACE, hepatic arterial infusion chemotherapy (HAIC) and transcatheater arterial radioembolization (TARE). Lp-TACE [also known as conventional TACE (cTACE)] has the widest clinical applications.

For patients with permitting liver function, lipiodol-TACE (Lp-TACE) should be the first treatment choice and can accurately stage and detect subcentimeter lesions and achieve organ level treatment. Lp-TACE as the first-line treatment for patients with intermediate stage HCC (2 to 3 lesions with diameters >3 cm or >3 lesions without portal vein tumor thrombus or extrahepatic metastasis) can effectively block the arterial blood supply to the liver tumor and continuously release a high concentration of chemotherapeutic drugs, which result in ischemic necrosis, shrinkage of the tumor, and control of tumor growth while having little effect on normal liver tissue. In Lp-TACE, ultra liquid lipiodol is fully mixed with chemotherapeutic drugs to form an emulsion, which is injected into the tumor blood supplying artery via microcatheter superselection. Commonly used chemotherapeutic drugs are anthracyclines and platinum, and combined administration is better than single drug use (47, 48). Enhanced embolization refers to the combination of gelatin sponge embolization with (after) Lp-TACE treatment, which can increase the efficacy of Lp-TACE. Drug-eluting bead (DEB)-TACE employs bead, which can carry a sufficient drug amount and slowly release chemotherapeutic drugs to achieve and maintain a lethal dose in the tumor tissue for several days to several weeks, while the drug concentration in systemic blood circulation is very low. After DEB-TACE treatment, the rate of tumor necrosis is high, and the adverse effects of systemic chemotherapy are mild. Previous study showed that the occurrence of locoregional complications and global hepatic damage after DEB-TACE, such as bile duct injury, intrahepatic biloma, and liver function impairment (presented as high baseline prothrombin value), was significantly higher than that with Lp-TACE alone and was more obvious in patients with severe cirrhosis (49). Moreover, the antitumor effect and overall survival between the two treatments are not significantly different (50–53). It is therefore suggested that Lp-TACE may be more appropriate than DEB-TACE in patients with less advanced cirrhosis.

Lp-TACE can provide diagnostic information and choice of treatment with the following advantages: 1. Induction of necrosis and tumor shrinkage to achieve a downstaging effect and obtain opportunities for surgery or ablation; 2. Detection of missed lesions on other imaging modalities, especially inconspicuous foci scattered small lesions; 3. Reduction of the blood supply inside and around the tumor, thereby reducing the impact of a heat sink effect; 4. Deposited lipiodol is has a positioning effect, thereby improving treatment accuracy (54, 55). For patients with early- and intermediate-stage HCC with good liver function, TACE treatment is recommended first (56). However, TACE alone cannot lead to complete tumor necrosis (the complete necrosis rate is only approximately 20%) and has difficulty destroying peripheral tumors surrounding the tumor lesion. Repeated TACE treatments impair liver function, and therefore, locally enhanced treatments, such as local ablation, surgery, and chemotherapy, are necessary to eliminate residual tumors. A repeated contrast-enhanced CT or MRI of the liver at 3 to 4 weeks after the initial TACE treatment is recommended. Subsequent combined ablation treatment can achieve a complete tumor necrosis rate of more than 90%. Repeated TACE treatments are not recommended because they can cause liver function impairment and aggravate cirrhosis. For tumors smaller than 5 cm, it is recommended to perform one TACE followed by combined ablation therapy; for tumors larger than 5 cm, subsequent combined ablation treatment can be performed after two to three TACE treatments (57, 58). On the basis of the follow-up evaluation, another TACE treatment, possibly in combination with other treatments, can be done if needed.

TARE is a trans-arterial interventional treatment in which 90Y or 131I microspheres or similar reagents are intra-arterially injected for continuous brachytherapy of cancer cells. The main indications of TARE include the following: 1. For the treatment of patients with a large tumor or multifocal or diffuse disease, which are not suitable for TACE; 2. For patients with portal vein tumor thrombus; 3. Disease progression after TACE or sorafenib treatment. Since arterial-venous or arterial-portal shunt
formation are common in patients with cirrhosis, the treatment efficacy of TARE is influenced. Therefore, its application still awaits further clinical confirmation (59, 60). In China, most liver cancer is accompanied by cirrhosis, and thus, the effects of TARE on cirrhosis also need further long-term observation.

Furthermore, when TACE cannot be performed due to liver dysfunction of the patients, CTHA, CTAP, or Lp-CT can still be performed for detection of subcentimeter lesions.

**Molecular Targeted Therapy**
Sorafenib and Lenvatinib, approved by the China Food and Drug Administration, are first-line treatment options for advanced HCCs (61). The STORM study suggested that adjuvant sorafenib after surgery to be ineffective (62). Retrospective studies have found that combined administration of sorafenib and TACE in the treatment of advanced liver cancer is superior to sorafenib alone (63–65); however, randomized controlled studies indicate that in European, American and Asian populations sorafenib administration on top of TACE does not improve treatment efficacy (66). The efficacy of sorafenib in adjuvant therapy after surgery, local ablation for early-stage patients, or in combination with TACE for intermediate-stage patients still awaits validation in larger cohorts of patients or prospective clinical studies.

**Radiation Therapy**
Radiation therapy consists of external radiotherapy involving external irradiation of tumors and internal radiotherapy in which the radionuclide is directly implanted into the tumor or lumen invaded by the tumor. In the past, due to less developed radiotherapy equipment, radiotherapy was prone to cause radiation-induced liver disease and aggravate liver dysfunction. Moreover, most liver cancer patients with cirrhosis tolerated the treatment poorly, and thus, the application of radiotherapy in HCC was limited. Since the mid-1990s, modern, precision radiotherapy techniques (e.g., three-dimensional conformal radiotherapy, intensity-modulated conformal radiotherapy, and stereotactic radiotherapy) have developed rapidly. Radiation therapy now is mature, and have been widely used in clinical practice (67). Radioactive particle implantation dose distribution is continuously optimized, achieving satisfactory results in liver cancer treatment, especially in the treatment of portal vein tumor thrombus and hilar lymph nodes (68).

**Biological Immunotherapy**
Immunotherapy for HCC primarily includes immunomodulators [interferon α, thymosin α1 (thymalfasin), etc.], immune checkpoint blockers [cytotoxic T lymphocyte-associated antigen (CTLA)-4 blocker, and programmed cell death protein 1 (PD-1) ligand (PD-L1) blocker], tumor vaccines (dendritic cell vaccines) and cellular immunotherapy [cytokine-induced killer (CIK)]. Biotherapy can improve antitumor efficacy and enhance immunity. Phase I/II clinical trials to assess immunotherapy have found that dendritic cell treatment is safe and effective for advanced HCC (69). Studies have shown that reduction of HCC tumor volume combined with dendritic cell-CIK biotherapy can postpone the time to tumor recurrence and benefit patient survival (70, 71). Comprehensive application of CIK in cancer therapy, especially in those with clinical evaluation of complete remission and radical removal of tumor load, is considered an effective method to prevent tumor recurrence (72).

**Traditional Chinese Medicine**
Many traditional Chinese medicine drugs and treatments are beneficial for reconstructing the immunity of patients, improving quality of life, reducing adverse reactions to radiotherapy and chemotherapy, and putting off tumor progression. In addition to decoction medicine, over the years, many proprietary Chinese medicines have been approved for HCC treatment, and each has their own characteristics and certain effects and has demonstrated good compliance, safety, and tolerance in patients (73). Traditional Chinese medicine advocates treatment of both the symptoms and cause of the disease. Removal of visible tumors treats the cancer-related symptoms but not the underline disease. Improving the constitutional environment and enhancing and improving immune function treat the causes and are important factors to prevent recurrence.

**Antiviral Treatment**
According to the “Expert consensus of antiviral treatment of HBV/HCV-related hepatocellular carcinoma” (74), antiviral treatment for HBV/HCV-related HCC patients can reduce the recurrence and mortality of HCC, decrease HBV/HCV reactivation, control disease progression, improve liver function, and reduce the occurrence of end-stage liver disease.

**Other Treatments**
Symptomatic supportive treatments primarily include analgesics, liver protection, chologues, improvement of nutritional status, correction of anemia and hypoproteinemia, control of ascites or pleural effusion, and prevention and treatment of gastrointestinal hemorrhage. These symptomatic supportive treatments can alleviate patient suffering, improve quality of life, ensure smooth progression of anticancer treatments, and even improve treatment efficacy or provide opportunity for further treatment.

**Comprehensive Treatment Principles and Multidisciplinary Comprehensive Treatment**
The proposed treatment algorithm of HCC is shown in Figure 2.

**EIGHT HIGHLIGHTS OF THE CONSENSUS**

**Hepatic Angiography, CTHA, CTAP, Lp-CT, and TACE-CT Are Useful in Detection of Focal Liver Lesions and Accurate Staging**
Imaging examinations play an important role in HCC diagnosis, and typical imaging characteristics indicating HCC are arterial phase enhancement and washout during the portal venous phase and delayed phase on CT or MRI, which have been included in the guidelines in different countries worldwide (75–78). However, the sensitivity of imaging examinations is limited, especially in the diagnosis of small HCC lesions. Moreover, HCC has multicenter origins and often exhibits early invasion of the small branches of the portal vein, intrahepatic metastasis,
FIGURE 2 | Multidisciplinary, comprehensive treatment model. TIPS: transjugular intrahepatic portosystemic shunt; PS (performance status) score: systemic condition test score; Massive type: maximum tumor diameter > 10 cm; Diffuse type: extensive and diffusely distributed intrahepatic cancer lesions with unclear borders, often accompanied by cirrhosis; Ablation: RFA, MWA, and PEI, among others, but primarily RFA and MWA; *Efficacy comparison of surgery and TACE combined with ablation awaits confirmation in further randomized multicenter clinical studies. **Treatment of portal vein invasion and extrahepatic metastasis should be based on control of intrahepatic lesions, which mostly requires multidisciplinary, comprehensive treatment. 1. Tumors in the safe area are preferably ablated. When a tumor is in a dangerous area and is not suitable for ablation, surgery is considered. 2. Ablation treatment can be repeated. For a tumor that is difficult to ablate in one treatment, the residual portion can be ablated again after follow-up examinations.
and high incidence of recurrence after liver resection. Therefore, early detection of small lesions in the liver and accurate evaluation of focal liver lesions and intrahepatic metastasis are important for disease treatment and prognosis assessment. Hepatic angiography, CT HA, CTAP, Lp-CT, and TACE-CT are useful in detection of focal liver lesions, accurate staging and planning of a suitable treatment regimen (Figures 3 and 4). TACE-CT can detect approximately 15% of lesions (most of which are < 5 mm or even < 3 mm) that are unrecognizable in a conventional CT scan (22–26).

**TACE/Ablation as the First Choice for Treatment of Early-Stage HCC**

The 2019 National Comprehensive Cancer Network (NCCN) guidelines recommend surgical resection or topical treatment for early-stage liver cancer (75). The third edition of the 2019 Japanese Liver Disease Association recommends surgical resection for patients with a single tumor and grade A or B liver function and further recommends RFA as an alternative regimen for patients with tumors smaller than 3 cm (77). The 2018 edition of the European Association of Liver Research guidelines recommend RFA for very early-stage liver cancer (BCLC stage 0) and surgical resection, liver transplantation and ablation treatment for early-stage liver cancer (BCLC stage A) (76). The 2019 edition of China specifications for diagnosis and treatment of primary liver cancer lists surgical resection and ablation as treatment options for early-stage liver cancer (78). Therefore, currently, whether surgical resection or ablation is the preferred treatment for early-stage liver cancer is still controversial.

At present, some clinical studies compared RFA and surgical resection in the treatment of a single small HCC (31, 32, 37, 79–83), and the controversial results remained. Peng et al. (37) enrolled 145 patients with early-stage HCC, of whom 71 underwent RFA and 74 underwent surgical resection. They found that RFA was superior in efficacy and safety to surgical resection, especially when the tumor lesions were more than 3 cm away from the Glisson’s capsule. Liu et al. (79) found that among 79 patients with RFA and 79 patients with surgical resection, tumor recurrence and survival were better in the surgical group than in the RFA group and concluded that surgical resection should be considered the preferred treatment method. Chen et al. (80) conducted a prospective, randomized, controlled study of patients with HCC ≤5 cm; 71 patients received RFA, and 90 patients underwent surgical resection. There was no survival difference between the two groups of patients, and subgroup analysis based on tumor size (≤3 cm and 3 to 5 cm) showed similar results. Therefore, the authors concluded that RFA, which is less invasive, had an efficacy similar to that of surgical resection. Huang et al. (81) compared RFA and surgical treatment for HCC patients with a single lesion <3 cm and found no difference in tumor control and survival between the 121 patients who underwent ablation and the 225 patients who underwent surgical resection, and the quality of life score in the ablation group was significantly better than that in the surgery group. Kang et al. (82) compared 198 patients with early-stage HCC using propensity-matching analysis and reached a similar conclusion that the efficacy of RFA treatment was comparable to that of surgical resection, and patients with RFA had fewer complications, faster recovery, and a significantly shortened hospitalization time. Kutlu et al. (83) used the US National Cancer Institute’s “surveillance, epidemiology, and end results (SEER) database” to conduct a large-scale study of 1,894 patients with HCC between 2004 and 2013 and found that there was no significant difference in the efficacy of RFA and surgical resection for tumors < 3 cm. Majumdar et al. (32) systematically reviewed four clinical studies that included 574 patients to compare RFA with

![FIGURE 3](image-url) | Imaging examination of an HCC patient with a progressively elevated AFP level. (A) CT plain scan showed no lesions in the liver; (B) A contrast-enhanced CT scan failed to reveal any lesions in the liver; (C) CTAP showed intrahepatic low-density lesions; (D) CTHA showed intrahepatic high-density lesions; (E) Lp-CT showed multiple intrahepatic lipiodol deposits after 3 weeks.
surgical resection and found that there was no significant difference in survival between the two treatments. In summary, ablation and surgery have similar efficacy in the treatment of early-stage HCC, and ablation is more advantageous from a health economics perspective (84). Therefore, the authors emphasize prioritizing interventional ablation treatment and only suggest surgical resection under circumstances when ablation is not appropriate.

TACE is a holistic treatment at the organ level and is applied at the first step of minimally invasive treatment. Its main role is to reduce tumor blood supply and reduce tumor load. Emulsified lipiodol and chemotherapeutic drugs are deposited in small lesions or foci that are difficult to detect by conventional contrast-enhanced CT scanning, thereby treating small lesions or foci while also revealing them and guiding the next step in minimally invasive treatment. TACE combined with ablation has demonstrated a higher survival rate and better tumor control rate than simple ablation and does not significantly increase the incidence of complications (85–87). Therefore, TACE/ablation has obvious advantages as a primary treatment for early-stage HCC (Figure 5).

Infiltrative HCC as an Independent Subtype
Infiltrative HCC is divided into diffuse and nondiffuse types. The imaging manifestation of infiltrative HCC is a lack of a clear boundary between tumor and normal liver tissue. Patients often have a history of cirrhosis. This HCC type accounts for approximately 7% to 13% of total HCC cases (14, 15). Risk factor analysis has shown that infiltrative HCC is more common in patients with HBV infection (88). Moreover, this type of HCC has diffuse distribution characteristics and is more likely to invade the portal vein system. Statistically, portal vein invasion in infiltrative HCC is much more common than in the noninfiltrating type (68% vs. 25%, P < 0.001) (14), and the prognosis of infiltrative HCC is worse than that of nodular type HCC with an intact capsule (Figure 6). Benvegnu et al. (88) reported that the 1-year and 3-year survival rates for HCC patients with an intact capsule were 75.4% and 46.0%, respectively, while those for infiltrative HCC patients were 33.3% and 13.6%, respectively. Kneuertz et al. (14) reported that the 1-year and 3-year survival rates for infiltrative HCC patients were 43% and 29%, respectively, and the median survival time was only 10 months.
The treatment options for infiltrative HCC are also limited because the majority of patients are in the advanced stage, and tumor infiltration and growth are typically accompanied by portal vein invasion, which is a contraindication for surgical resection and liver transplantation. Transarterial intravascular treatment is an effective and feasible treatment for infiltrative HCC. Studies conducted by Lyu et al. (89, 90) indicated that HAIC for patients with advanced HCC accompanied by portal vein tumor thrombus was effective. A phase II, single-arm clinical trial showed that 49 patients achieved a good tumor control rate, a considerable survival rate, fewer adverse reactions, and a higher quality of life after treatment. Further comparison with administration of oral sorafenib, a targeted drug, showed that the median progression-free survival time of the HAIC group was longer than that of the sorafenib group [based on the modified response evaluation criteria in solid tumors (mRECIST), 7.4 months vs. 3.6 months, \( P < 0.001 \)] and the median survival time was better than that of the sorafenib group (14.5 months vs. 7.0 months, \( P < 0.001 \)). In the meantime, a study of 147 propensity matched pairs further confirmed the reliability of the results. Multivariate regression analysis also confirmed that HAIC was a favorable factor for tumor control \( (P < 0.001) \) and extended survival time \( (P < 0.001) \) of patients. For specific protocols for hepatic arterial infusion chemotherapy, refer to the literature (91).

**Minimally Invasive and Comprehensive Treatment of Metastatic Lymph Nodes**

In advanced patients with extrahepatic metastases via molecular targeted therapy (sorafenib), although effective, extends survival time by only 3 months. Furthermore, patients at this stage usually die of intrahepatic lesion progression rather than extrahepatic metastasis. Therefore, multidisciplinary comprehensive therapy consisting of treatment of intrahepatic lesions combined with local treatment of extrahepatic metastases is still advocated (92–97) (**Figure 7**). The principles of treatment are as follows: 1. Protection of lymph nodes with normal function; 2. Inactivation of metastatic lymph nodes; 3. Close observation and follow-up of suspect lymph nodes.
Multilevel Subdivision of M Staging Used for Guiding Treatment and Predicting Prognosis

Stage IV HCC should be subdivided to distinguish patients with limited metastasis from patients with a heavy metastatic tumor load. For example, patients with a single metastatic lesion in a single metastatic organ are defined as M1-1, patients with multiple metastatic lesions in a single metastatic organ are defined as M1-m, and so on (Table 1). For patients at different stages, limited metastatic lesions can be eliminated by ablation or particle implantation, resulting in longer survival (93, 94, 97) (Figure 8), rather than treated by administration of a molecular targeted drug alone as suggested in the guidelines.

HCC Patients With Severe Hepatic Decompensation Are Candidates for Liver Transplantation

In recent years, immunotherapy has become a research hotspot and is the future trend in cancer treatment. The 2018 Nobel Prize
in Medicine was awarded to two cancer immunotherapy scientists. Tumor immunotherapy is a treatment method for controlling and clearing tumors by reactivating and maintaining the recognition and killing abilities of the immune system toward tumor cells and restoring the normal antitumor immune responses of the body. Some studies suggested that future cancer treatment should be combined with immunotherapy rather than employ a single treatment regimen (98). The CheckMate 040 phase I/II phase clinical trial validated the efficacy and safety of the anti-PD-1 antibody nivolumab in patients with advanced HCC (99). In March 2020, the US Food and Drug Administration (FDA) approved nivolumab plus ipilimumab for HCC previously treated with sorafenib (100). However, liver transplant patients, who suffer from tremendous surgical trauma, need relatively longer recovery time, require many economic and medical resources, and still have issues of recurrence and metastasis. In the meantime, long-term use of immunosuppressive agents is required after surgery, and thus, the valuable opportunity for immunotherapy is missed for many patients, which conflicts with the future direction of cancer treatment.

TABLE 1 | Multilevel subdivision of M staging.

| M staging | Criteria |
|-----------|----------|
| M1-1      | 1 organ, 1 metastatic lesion |
| M1-2      | 1 organ, 2 metastatic lesions |
| M1-3      | 1 organ, 3 metastatic lesions |
| M1-4      | 1 organ, 4 metastatic lesions |
| M1-m      | 1 organ, multiple metastatic lesions |
| M2-2      | 2 organs, 2 metastatic lesions |
| M3-3      | 3 organs, 3 metastatic lesions |
| Mm-m      | > 3 organs, ≥ 5 metastatic lesions |

M, metastasis; m, multiple.

FIGURE 7 | Minimally invasive, comprehensive treatment for metastatic lymph nodes. (A) S4 HCC with metastatic lymph nodes in the portal vena cava space that were pathologically confirmed as HCC. The AFP level was 439 ng/mL before treatment; (B) Two weeks after TACE treatment, subsequent RFA was performed; (C) RFA ablation of hepatic portal metastatic lymph nodes; (D) Lymph nodes were basically inactivated, and 125I particles were implanted in the remaining portion; (E) Metastatic lymph nodes were completely necrotic, and the AFP level decreased to 14 ng/mL; (F) After adjuvant CIK treatment, the metastatic lymph nodes were completely inactivated, and AFP was further reduced to 2 ng/mL. The patient is still alive 10 years after treatment.

Promotion of Bioimmunotherapy, Traditional Chinese Medicine Therapy, Antiviral Therapy, and Psychosocial and Psychopharmacological Interventions, Which Should Be Involved in All Stages of Treatment

Liver cancer requires treatment of both the symptoms and the underlying basic causes. Direct treatment of tumors is treatment of the symptoms, and protection of a patient’s biological immune functions and establishment of excellent psychosocial support treat the underlying basis. HCC is an inflammation-related cancer, and studies have confirmed that immune remission is associated with tumor and patient outcome (101). Biotherapy can strengthen a patient’s immunity and ultimately improve antitumor effects (Figure 9). Current immuno-therapeutic strategies are based on two fundamental principles: 1. The ability to evoke current immune responses; 2. The need to stimulate new or different immune responses. Unleashing current immune response relies on reactivity of a pre-existing immunity to cancer which is restricted by micro-environmental factors, such as inhibitory receptors on T cells especially PD-1 and CTLA-4, or alternatively immunosuppressive cytokines such as TGF-β. Checkpoint inhibitors fall within this category. Conversely, antibodies that directly target molecules expressed on HCC, such as alpha-AFP, are within the second category. These strategies can be enhanced by coupling these antibodies to effector cells, such as T cells or even NK cells. The first-line checkpoint inhibitors approved for use in HCC by NCCN (75) are as following: Atezolizumab + bevacizumab is preferred regimens, while Nivolumab + ipilimumab is preferred for use in HCC. Nivolumab is applicable if patient is ineligible for tyrosine kinase inhibitors (TKIs) or other anti-angiogenic agents. As subsequent-line therapy if disease progression, Nivolumab,
Nivolumab + ipilimumab, Ramucirumab, and Pembrolizumab are optional.

Efficient combination of the various drugs and treatment methods provided by traditional Chinese medicine can enhance the body’s immunity, reduce adverse reactions to radiotherapy and chemotherapy, and improve the quality of life of patients. In addition to decoction medicine, the China drug regulatory authorities have approved several modern Chinese medicine preparations for HCC treatment (102), and all have demonstrated unique characteristics and certain effects, with good patient compliance, safety and tolerance, and thus can be used as appropriate. Sustained infection with HBV and/or HCV is an important risk factor for HCC development, progression, and recurrence. Antiviral therapy is very important in liver cancer patients with HBV infection and active replication of the virus. Antiviral therapy can reduce the rate of postoperative recurrence (103, 104). Therefore, antiviral therapy should be involved throughout the liver cancer treatment process. The mental status of patients with liver cancer and their families should be considered, and effective measures should be employed to help them face the disease positively and to reduce depression, fear, and anxiety.

However, the treatment strategy for clinical patients should be made according to their own characteristics, so that patients can get the most benefit from treatment. Bioimmunotherapy, traditional Chinese medicine therapy, antiviral therapy, and psychosocial and psychopharmacological interventions cover a very wide area involving multidisciplinary approach. Therefore, determination of appropriate therapy should include a careful patient/physician discussion. Many clinical trials on combined treatments for HCC are ongoing, including assessing combinations with immune checkpoint inhibitors. Further clinical evidences are required to
explore the reliable treatment schedule, which might allow a more precise selection of treatment in well-defined patients.

**Implementation of Multicenter, Randomized, Controlled Studies of Minimally Invasive Treatment and Surgery for Early- and Intermediate-Stage HCC**

In choosing treatment methods for early- and intermediate-stage HCC, there are still major differences in different countries and in different disciplines (96), and multicenter, randomized, controlled studies are lacking. For example, in the newly published China Liver Cancer 2019 guidelines, there are three treatment options for early-stage liver cancer: surgery, ablation, and liver transplantation. These three completely different treatment methods confuse both patients and doctors. The aforementioned questions still await verification in additional large-scale multicenter randomized controlled studies. Therefore, conducting multicenter, randomized, controlled clinical studies of minimally invasive and surgical treatments for early- and intermediate-stage HCC is recommended.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

**AUTHOR CONTRIBUTIONS**

All authors discussed the recommendations. Q-FC, WL, and PW developed the first outline. All the authors were involved in revising when the first draft had been developed. All the authors refined the contents with feedbacks, and comments. All authors contributed to the article and approved the submitted version.

**REFERENCES**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: Cancer J Clin (2018) 68 (6):394–424. doi: 10.3322/caac.21492
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer Statistics in China, 2015. CA: Cancer J Clin (2016) 66(2):115–32. doi: 10.3322/caac.21338
3. Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, et al. Hepatitis B and C Virus Infection and Hepatocellular Carcinoma in China: A Review of Epidemiology and Control Measures. J Epidemiol (2011) 21(6):401–16. doi: 10.2188/jea.JE20101190
4. Cohen GS, Black M. Multidisciplinary Management of Hepatocellular Carcinoma: A Model for Therapy. J Multidiscip Healthcare (2013) 6:189–95. doi: 10.2147/JMDH.S41206
5. Dong A, Li W, Dong J, Li S, Shen L, Zhang Z, et al. Strategies of Minimally Invasive and Multidisciplinary Diagnosis and Treatment for Hepatocellular Carcinoma in China. Zhonghua yi xue za zhi (2015) 95(21):1702–6. doi: 10.3760/cma.j.issn.0376-2491.2015.21.020
6. Zhang BH, Yang BH, Tang ZY. Randomized Controlled Trial of Screening for Hepatocellular Carcinoma. J Cancer Res Clin Oncol (2004) 130(7):417–22. doi: 10.1007/s00432-004-0552-0
7. Elefftheriou N, Heathcoat J, Thomas HC, Sherlock S. Serum Alpha-Fetoprotein Levels in Patients With Acute and Chronic Liver Disease. Relation to Hepatocellular Regeneration and Development of Primary Liver Cell Carcinoma. J Clin Pathol (1977) 30(8):704–8. doi: 10.1113/jcp.30.8.704
8. Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, et al. Des-Gamma-Carboxyprothrombin, Alpha-Fetoprotein and AFP-L3 in Patients With Chronic Hepatitis. Cirrhosis and Hepatocellular Carcinoma. J Gastroenterol Hepatol (2008) 23(10):1541–4. doi: 10.1111/j.1440-1746.2008.05359.x
9. Xu RH, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, et al. Circulating Tumour DNA Methylation Markers for Diagnosis and Prognosis of Hepatocellular Carcinoma. Nat Mater (2017) 16(11):1155–61. doi: 10.1038/nmat4997
10. Chen BB, Murakami T, Shih TT, Sakamoto M, Matsui O, Choi BI, et al. Novel Imaging Diagnosis for Hepatocellular Carcinoma: Consensus From the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer (2015) 4(1):25–27. doi: 10.1159/000367742
11. Merkle EM, Zech CJ, Bartolozzi C, Bashir MR, Ba-Salamah A, Huppertz A, et al. Consensus Report From the 7th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol (2016) 26(3):674–82. doi: 10.1007/s00330-015-3873-2
12. Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, et al. Diagnosis of Hepatic Nodules 20 Mm or Smaller in Cirrhosis: Prospective Validation of the Noninvasive Diagnostic Criteria for Hepatocellular Carcinoma. Hepatology (2008) 47(1):97–104. doi: 10.1002/hep.21966
13. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver Consensus Recommendations on Hepatocellular Carcinoma. Hepatol Int (2010) 4(2):439–74. doi: 10.1007/s12072-010-9165-7
14. Kneuertz PJ, Demirjian A, Firoozmand A, Corona-Villalobos C, Bhagat N, Herman J, et al. Diffuse Infiltrative Hepatocellular Carcinoma: Assessment of Presentation, Treatment, and Outcomes. Ann Surg Oncol (2012) 19(9):2897–907. doi: 10.1245/s10434-012-2336-0
15. Demirjian A, Peng P, Geschwind JF, Cosgrove D, Schuett J, Kamel IR, et al. Infiltrating Hepatocellular Carcinoma: Seeing the Tree Through the Forest. J Gastrointestinal Surg: Off J Soc Surg Alimentary Tract (2011) 15(11):2089–97. doi: 10.1007/s11605-011-1614-7
16. Yu MH, Kim JH, Yoon JH, Kim HC, Chung JW, Han JK, et al. Small (<1-Cm) Hepatocellular Carcinoma: Diagnostic Performance and Imaging Features at Gadoteric Acid-Enhanced MR Imaging. Radiology (2014) 271(3):748–60. doi: 10.1148/radiol.14131996
17. Makita O, Yamashita Y, Arakawa A, Nakayama Y, Mitsuzaki K, Ando M, et al. Diagnostic Accuracy of Helical CT Arteriography and CT Hepatic Arteriography for Hypervascular Hepatocellular Carcinoma in Chronic Liver Damage. An ROC Analysis. Acta Radiol (2000) 41(5):464–9. doi: 10.1038/sj.dra.19003569
18. Ohki T, Tateishi R, Akahane M, Shimai S, Mashima N, Mikami S, et al. Characteristics of Hepatocellular Carcinoma Nodules Newly Detected by Computed Tomography During Arteriography and Arterial Portography: Preliminary Report of a Randomized Controlled Trial. Hepatol Int (2012) 6(3):639–45. doi: 10.1007/s12072-011-9310-y
19. Ohki T, Tateishi R, Akahane M, Mikami S, Sato M, Uchino K, et al. CT With Haptic Arteriography as a Pretreatment Examination for Hepatocellular Carcinoma Patients: A Randomized Controlled Trial. Am J Gastroenterol (2013) 108(8):1305–13. doi: 10.1038/ajg.2013.109
20. Kito A, Zen Y, Matsu O, Gabata T, Nakanuma Y. Hepatocarcinogenesis: Multistep Changes of Drainage Vessels at CT During Arterial Portography and Hepatic Arteriography–Radiologic-Pathologic Correlation. Radiology (2009) 252(2):605–14. doi: 10.1148/radiol.2522081414
21. Nishie A, Tajima T, Asayama Y, Ishigami K, Hikawaka M, Ushijima Y, et al. Radiological Assessment of Hepatic Vein Invasion by Hepatocellular Carcinoma Using Combined Computed Tomography Hepatic Arteriography and Computed Tomography Arterial Portography. Jpn J Radiol (2010) 28(6):414–22. doi: 10.1007/s11694-010-0442-0
22. Rizvi S, Camci C, Yong Y, Parker G, Shrago S, Stokes K, et al. Is Post-Lipiodol CT Better Than I.V. Contrast CT Scan for Early Detection of HCC?: A Single Liver Transplant Center Experience. Transplant Proc (2006) 38(9):2993–5. doi: 10.1016/j.transproceed.2006.08.125
23. Zheng XH, Guan YS, Zhou XP, Huang J, Sun L, Li X, et al. Detection of Hypervascular Hepatocellular Carcinoma: Comparison of Multi-Detector
Abitabile P, Hartl U, Lange J, Maurer CA. Radiofrequency Ablation Permits the Detection of Small Hepatocellular Carcinoma: Correlation With Pathologic Examination of Explanted Livers. J Hepatol (1998) 28(3):491–6. doi: 10.1016/S0168-8278(98)00324-3

Bartolozzi C, Lencioni R, Caramella D, Palla A, Bassi AM, Di Candio G. Small Hepatocellular Carcinoma. Detection With US, CT, MR Imaging, DSA, and Lipiodol-CT. Acta Radiol (1996) 37(1):69–74. doi: 10.1177/028418519603701114

Marcato N, Abergel A, Alexandre M, Boire JY, Darcha C, Duchene B, et al. (Hepatocellular Carcinoma in Cirrhosis: Semiology and Performance of Magnetic Resonance Imaging and Lipiodol Computed Tomography). Gastroenterol Clin Biol (1999) 23(1):114–21.

Wu P, Zhang F, Wu Z. Normally Invasive and Multidisciplinary Diagnosis and Treatment for Hepatocellular Carcinoma. Beijing: Military Medical Science Press (2003).

Caturelli E, de Sio I. Biopsy Diagnosis of Hepatocellular Carcinoma. Hepatology (2008) 47(6):2145. doi: 10.1002/hep.22282

Qi X, Zhao Y, Li H, Guo X, Han G. Management of Hepatocellular Carcinoma: A Randomized Clinical Trial. Chin J Cancer (2006) 25(12):801–5. doi: 10.3736/jissn:0376-2491.2006.12.003

Duan C, Liu M, Zhang Z, Ma K, Bie P. Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Early-Stage Hepatocellular Carcinoma Meeting Milan Criteria: A Systematic Review and Meta-Analysis. Cochrane Database Syst Rev (2017) 3:C0011650. doi: 10.1002/14651858.CD0011650.pub2

Lu MD, Kuang M, Liang LJ, Xie XY, Peng BG, Liu GJ, et al. CT Portography and Post-Lipiodol CT in the Preinterventional Work-Up of Primary and Secondary Liver Tumors. A Single Center Experience. Hepato-Gastroenterology (1999) 46(29):2901–8.

Bizollon T, Rode A, Bancel B, Gueripel V, Duchene B, et al. CT With Pathologic Correlation. Invest Radiol (2012) 47(1):671–5. doi: 10.1097/RLI.0b013e3182724bdfd

Lencioni R, de Baere T, Soulen MC, Billing WS, Geschwind JF. Lipiodol Transarterial Chemoembolization for Hepatocellular Carcinoma: A Systematic Review of Efficacy and Safety Data. Hepatology (2016) 64 (1):106–16. doi: 10.1002/hep.28453

Shi M, Lu LG, Fang WQ, Guo RP, Chen MS, Li Y, et al. Roles Played by Chemolipiodisation and Embolization in Chemoembolization for Hepatocellular Carcinoma: Single-Blind, Randomized Trial. J Natl Cancer Inst (2013) 105(1):59–68. doi: 10.1093/jnci/djs464

Monier A, Guieu B, Duran R, Aho S, Bize P, Deltenre P, et al. Liver and Biliary Damages Following Transarterial Chemoembolization of Hepatocellular Carcinoma: Comparison Between Drug-Eluting Beads and Lipiodol Emulsion. Eur Radiol (2017) 27(4):1431–9. doi: 10.1007/s00330-016-4888-y

Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Waterkinson A, et al. Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study. Cardiovasc Interventional Radiol (2010) 33(1):41–52. doi: 10.1007/s00270-009-9711-7

Martin R, Geller D, Espat J, Kooby D, Sellers M, Goldstein R, et al. Safety and Efficacy of Transarterial Chemoembolization With Drug-Eluting Beads in Hepatocellular Cancer: A Systematic Review. Hepato-gastroenterology (2012) 59(113):255–60. doi: 10.5755/jhg.10204

Gao S, Yang Z, Zheng Z, Yao J, Deng M, Xie H, et al. Doxorubicin-Eluting Bead Versus Conventional TACE for Unresectable Hepatocellular Carcinoma: A Meta-Analysis. Hepato-Gastroenterology (2013) 60(124):813–20. doi: 10.5755/jhg.121025

Karalli A, Teiler J, Haji M, Seth E, Brismar TB, Wahlin S, et al. Comparison of Lipiodol Infusion and Drug-Eluting Beads Transarterial Chemoembolization of Hepatocellular Carcinoma in a Real-Life Setting. Scand J Gastroenterol (2019) 54 (7):905–12. doi: 10.1080/00365521.2019.1632925

Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, et al. Report of a National Conference on Liver Allocation in Patients With Hepatocellular Carcinoma in the United States. Liver Transplant: Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc (2010) 16(3):262–78. doi: 10.1002/ft.21999

Shi F, Wu M, Lian SS, Mo ZQ, Gou Q, Xu RD, et al. Radiofrequency Ablation Following Downstaging of Hepatocellular Carcinoma by Using Transarterial Chemoembolization: Long-Term Outcomes. Radiology (2019) 293(3):707–15. doi: 10.1148/radiol.2019181991

Gu L, Liu H, Fan J, Li Y, Zou L, Liu Y, et al. Treatment Outcomes of Transarterial Arterial Chemoembolization Combined With Local Ablative Therapy Versus Monotherapy in Hepatocellular Carcinoma: A Meta-Analysis. J Cancer Res Clin Oncol (2014) 140(2):199–210. doi: 10.1007/s00432-013-1528-8
57. Zhao M, Wang JP, Wu PH, Zhang FJ, Huang ZL, Li W, et al. [Comparative Analysis of TACE Alone or Plus RFA in the Treatment of 167 Cases of Intermediate and Advanced Stage Primary Hepatocellular Carcinoma]. Zhonghua yi xue za zhi (2010) 90(41):2916–21. doi: 10.3766/cma.jsnn.0376-2491.2010.41.009

58. Chen Q, Jia ZY, Yang QZ, Fan WL, Shi HB. Transarterial ChemoeMBOLization Monotherapy Versus Combined Transarterial ChemoeMBOLization-Microwave Ablation Therapy for Hepatocellular Carcinoma Tumors <=5 Cm: A Propensity Analysis at a Single Center. Cardiovasc Interventional Radiol (2017) 40(1):1748–55. doi: 10.1007/s00270-017-1736-8

59. Lau WY, Sangro B, Chen PJ, Cheng SQ, Chow P, Lee RC, et al. Treatment for Hepatocellular Carcinoma With Portal Vein Thrombosis: The Emerging Role for Radioembolization Using Yttrium-90. Oncology (2013) 84(5):311–8. doi: 10.1159/000348325

60. Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, et al. Combination Trans Arterial Chemoembolization of Combined Transarterial Chemoembolization-Microwave Ablation Therapy for Hepatocellular Carcinoma: The SPACE Trial. J Cancer Res Clin Oncol (2016) 142(6):1241–50. doi: 10.1007/s00432-016-2045(15):00198-9

61. Eabc-Rahman O, Elsayed ZA. Combination Trans Arterial Chemoembolization of Combined Transarterial Chemoembolization-Microwave Ablation Therapy for Hepatocellular Carcinoma: The SPACE Trial. J Cancer Res Clin Oncol (2016) 142(6):1241–50. doi: 10.1007/s00432-016-2045(15):00198-9

62. Fu QH, Zhang Q, Bai XL, Hu QD, Su W, Chen YW, et al. Sorafenib or Placebo Plus TACE With Doxorubicin-Eluting Beads for Intermediate Staged Primary Hepatocellular Carcinoma: A Systematic Review of the Literature. J Hepatol (2016) 65(1):28–37. doi: 10.1016/j.jhep.2016.01.012

63. Chen Q, Shu C, Laurence AD, Chen Y, Peng BG, Zhen ZL, et al. Effect of Huaiar Granule on Recurrence After Curative Resection of HCC: A Multicentre, Randomised Clinical Trial. Gut (2018) 67(11):2006–16. doi: 10.1136/gutjnl-2018-319583

64. Ye Z. [Expert Consensus on Antiviral Therapy to Treat Hepatitis B/C Virus-Related Hepatocellular Carcinoma]. Zhonghua gan zang bing za zhi = Chin J Hepatol (2014) 22(5):321–6. doi: 10.3766/cma.jsnn.1007-3418.2014.05.001

65. Benson AB, D’Angelica MI, Abbott DE, Abrams TA, Alberts SR, Anaya DA, et al. Guidelines Insights: Hepatobiliary Cancers, Version 2.2019. J Natl Compr Cancer Network: JNCCN (2019) 17(4):302–10. doi: 10.6004/jnccn.2019.0019

66. European Association for the Study of the Liver, Electronic address eee and European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. J Hepatol (2018) 69(1):182–236. doi: 10.1016/j.jhep.2018.03.019

67. Shen L, Xi M, Zhao L, Zhang X, Wang X, Huang Z, et al. Combination Therapy After TACE for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy Versus Sorafenib. Int J Radiat Oncol Biol Phys (2018) 101(2):351–6. doi: 10.1016/j.ijrobp.2017.12.004

68. Park MK, Gwak GY, Choo GH, Yang J, Kudo M, et al. Adjuvant Sorafenib for Hepatocellular Carcinoma After Resection or Ablation (STORM): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial. Lancet Oncol (2015) 16(13):1344–54. doi: 10.1016/S1470-2045(15)00198-9

69. Lucchini R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, et al. Sorafenib or Placebo Plus TACE With Doxorubicin-Eluting Beads for Intermediate Stage HCC: The SPACE Trial. J Hepatol (2016) 64(5):1090–8. doi: 10.1016/j.jhep.2016.01.012

70. Shen L, Xi M, Zhao L, Zhang X, Wang X, Huang Z, et al. Combination Therapy After TACE for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy Versus Sorafenib. Int J Radiat Oncol Biol Phys (2018) 101(2):351–6. doi: 10.1016/j.ijrobp.2017.12.004

71. Zhao M, Hsia CY, Lee YH, Huang YH, Chiou YY, et al. Cytokine-Induced Killer Cell Fusion to Lower Recurrence of Hepatocellular Carcinoma After Radiofrequency Ablation. J Immunother (2012) 35(7):630–5. doi: 10.1007/s12137-011-0274-9

72. Huang ZM, Li W, Li S, Gao F, Zhou QM, Wu FM, et al. Cytokine-Induced Killer Cells in Combination With Transcatheter Arterial Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Patients. J Immunother (2013) 36(5):287–93. doi: 10.1097/CJI.0b013e3182950f8a

73. Lucchini R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, et al. Sorafenib or Placebo Plus TACE With Doxorubicin-Eluting Beads for Intermediate Stage HCC: The SPACE Trial. J Hepatol (2016) 64(5):1090–8. doi: 10.1016/j.jhep.2016.01.012

74. Tada F, Abe M, Hirooka M, Ikeda Y, Hiasa Y, Lee Y, et al. Phase II Study of Immunotherapy Using Tumor Antigen-Impulsed Dendritic Cells in Patients With Hepatocellular Carcinoma. Int J Oncol (2012) 41(5):1601–9. doi: 10.3892/ijo.2012.1626

75. Huang Z, Li W, Li S, Gao F, Zhou QM, Wu FM, et al. Cytokine-Induced Killer Cells in Combination With Transcatheter Arterial Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Patients. J Immunother (2013) 36(5):287–93. doi: 10.1097/CJI.0b013e3182950f8a

76. Takayama T, Sekine T, Mukuchi M, Yamashita S, Kousuge T, Yamamoto J, et al. Adoptive Immunotherapy to Lower Postsurgical Recurrence Rates of Hepatocellular Carcinoma: A Randomised Trial. Lancet (2000) 356(9232):402–6. doi: 10.1016/S0140-6736(00)02654-4

77. Chen Q, Shu C, Laurence AD, Chen Y, Peng BG, Zhen ZL, et al. Effect of Huaiar Granule on Recurrence After Curative Resection of HCC: A
89. Lyu N, Lin Y, Kong Y, Zhang Z, Liu L, Zheng L, et al. FOXAI: A Phase II Trial Evaluating the Efficacy and Safety of Hepatic Arterial Infusion of Oxaiplatin Plus Fluorouracil/Leucovorin for Advanced Hepatocellular Carcinoma. Gut (2018) 67(2):395–6. doi: 10.1136/gutjnl-2017-314138

90. Lyu N, Kong Y, Mu L, Lin Y, Li J, Liu Y, et al. Hepatic Arterial Infusion of Oxaiplatin Plus Fluorouracil/Leucovorin vs. Sorafenib for Advanced Hepatocellular Carcinoma. J Hepatol (2018) 69(1):60–9. doi: 10.1016/j.jhep.2018.02.008

91. Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, et al. Randomized, Multicenter, Open-Label Study of Oxaiplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin as Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia. J Clin Oncol: Off J Am Soc Clin Oncol (2013) 31(28):3501–8. doi: 10.1200/JCO.2012.44.5643

92. Pan T, Xie QK, Lv N, Li XS, Mu LW, Wu PH, et al. Percutaneous CT-Guided Radiofrequency Ablation of Hepatocellular Carcinoma: A Propensity Score-Matching Analysis. Radiology (2017) 282(1):259–70. doi: 10.1148/radiol.2016151807

93. Lee HS. Management of Patients With Hepatocellular Carcinoma and Extrahepatic Metastasis. Digestive Dis (2011) 29(3):333–8. doi: 10.1159/000327572

94. Gao F, Gu YK, Huang JH, Zhao M, Wu PH, et al. Percutaneous CT-Guided Radiofrequency Ablation for Lymph Node Oligometastases From Hepatocellular Carcinoma: A Propensity Score-Matching Analysis. Radiology (2017) 282(1):259–70. doi: 10.1148/radiol.2016151807

95. Lyu N, Lin Y, Kong Y, Zhang Z, Liu L, Zheng L, et al. FOXAI: A Phase II Trial Evaluating the Efficacy and Safety of Hepatic Arterial Infusion of Oxaiplatin Plus Fluorouracil/Leucovorin for Advanced Hepatocellular Carcinoma. Gut (2018) 67(2):395–6. doi: 10.1136/gutjnl-2017-314138

96. Xu XL, Liu XD, Liang M, Luo BM. Radiofrequency Ablation Versus Doxorubicin as Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma. J Hepatol (2006) 45(6):868–78. doi: 10.1016/j.jhep.2006.09.004

97. Shen L, Li W, Wang S, Xie G, Zeng Q, Chen C, et al. Image-Based Multilevel Subdivision of M1 Category in TNM Staging System for Metastatic Nasopharyngeal Carcinoma. Radiology (2016) 280(3):805–14. doi: 10.1148/ radiol.2016151344

98. Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The Future of Cancer Treatment: Immunomodulation, CARs and Combination Immunotherapy. Nat Rev Clin Oncol (2016) 13(5):273–90. doi: 10.1038/nrclonc.2016.25

99. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in Patients With Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. Lancet (2017) 389(10088):2492–502. doi: 10.1016/S0140-6736(17)31046-2

100. Wright K. FDA Approves Nivolumab Plus Ipilimumab for the Treatment of Advanced HCC. Oncol (Williston Park) (2020) 34(4):693606.

101. Greten TF, Manns MP, Korangy F. Immunotherapy of Hepatocellular Carcinoma. J Hepatol (2006) 45(6):868–78. doi: 10.1016/j.jhep.2006.09.004

102. Gao JL. [Prospective Randomized Controlled Study on Advanced Primary Hepatic Cancer Treated by Ganfule Prescription]. Zhongguo zhi xue za zhi = Zongguo zhe xue za zhi = China J Chin Mater Med (2014) 39(12):2367–9. doi: 10.4268/cjcm20141243

103. Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, et al. Effect of Anti viral Treatment With Nucleotide/Nucleoside Analogs on Postoperative Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Two-Stage Longitudinal Clinical Study. J Clin Oncol: Off J Am Soc Clin Oncol (2013) 31(29):3647–55. doi: 10.1200/JCO.2012.48.5896

104. Huang G, Lau WY, Wang ZG, Pan ZY, Yuan SX, Shen F, et al. Antiviral Therapy Improves Postoperative Survival in Patients With Hepatocellular Carcinoma: A Randomized Controlled Trial. Ann Surg (2015) 261(1):56–66. doi: 10.1097/SLA.0000000000000858

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Chen, Li, Yu, Chou, Rhim, Yang, Shen, Dong, Huang, Zhang, Fan, Zhou, Gu, Huang, Zuo, Zhai, Xiao, Kuang, Li, Han, Song, Ma and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.